New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACE Videos and Articles

 

Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation